Abbott has been recognised by the Consumer Technology Association (CTA) with three Consumer Electronics Show (CES 2023; 5–8 January, Las Vegas, USA) Innovation Awards for multiple technologies that are said to be “advancing the health tech industry and improving the lives of people worldwide”.
All three of the following technologies are set to win CES 2023 awards within the Digital Health award category early next year:
- Aveir VR leadless pacemaker—the “world’s only” leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and designed to be completely retrievable, which was developed by Abbott to treat patients with slow heart rhythms, and eliminates wires used to deliver therapy in traditional pacemakers
- Proclaim Plus spinal cord stimulation (SCS) system—Abbott’s latest advancement in neurostimulation therapy to treat chronic pain using low doses of targeted BurstDR stimulation that can be adjusted as a person’s therapeutic needs evolve across up to six areas of the body, which is “more pain sites in the body than ever before”
- Alinity m monkeypox polymerase chain reaction (PCR) test—a “first-of-its-kind” diagnostic that Abbott received US Food and Drug Administration (FDA) Emergency Use Authorisation for detecting the monkeypox virus with
The CES Innovation Awards programme is an annual competition honouring outstanding design and engineering in consumer technology products. It recognises the year’s most innovative products in a multitude of consumer technology product categories and distinguishes the highest-rated in each, an Abbott press release details.
Last year, Abbott became the first healthcare company to keynote CES, and it has also received nine CES Innovation Awards in the past two years.